Neto FS et al., 2023-10-18: Multicentre single-blind randomised superiority trial in 315 patients with dysuria: methenamine 250 mg plus methylthioninium chloride 20 mg gave a 12.7 percentage-point higher excellent-response rate within 24 hours than phenazopyridine.
This study evaluated the combination of methenamine 250 mg and methylthioninium chloride 20 mg in the treatment of dysuria versus phenazopyridine.
Abstract
Neto FS et al., 2023-10-18: Multicentre single-blind randomised superiority trial in 315 patients with dysuria: methenamine 250 mg plus methylthioninium chloride 20 mg gave a 12.7 percentage-point higher excellent-response rate within 24 hours than phenazopyridine. Study type: multicentre, single-blind, randomised, superiority clinical trial. N=315 adults with dysuria and pain score >=5. Intervention: methenamine 250 mg + methylthioninium chloride 20 mg orally (fixed combination); comparator phenazopyridine. Primary outcome: excellent clinical response within 24 h (difference 12.7%, 95% CI 6.16-19.21 for pain). Conflicts (declared verbatim): 'All authors were principal investigators of their respective research centers and received a fee for including patients in the study.' Country: Brazil. Note: the endpoint is symptom relief of dysuria, not eradication of infection , the trial does not show MB treats UTI. Also filed as MTN-32, MTD-027, MTI-87 (claims C5, C6, C7, C8). Study type: randomized trial.
